このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

肺気腫における肺容量減少のための葉間裂完了を伴う複合ゼファーバルブシステム (COMPLETE-1)

2026年11月9日 更新者:Adnan Majid, MD、Beth Israel Deaconess Medical Center

肺気腫における肺容積減少のための葉間裂完了を伴う複合ゼファーバルブシステム:パイロット無作為対照試験

The purpose of this protocol is to perform a pilot prospective randomized controlled clinical trial to evaluate the potential role of lung fissure completion strategy (experimental intervention) in addition to endobronchial valve (EBV) placement (representing "standard-of-care") in select patients with severe COPD/emphysema and with evidence for <95% fissure completion between adjacent lung lobes. In select patients, lung fissure completion strategy will be performed by either video-assisted thorascopic surgery (VATS)-guided or robotic-guided stapling along the lung fissures in an attempt to reduce collateral ventilation and determine whether or not this experimental strategy will improve outcome following subsequent EBV placement. EBV placement will follow successful VATS-guided or robotic-guided fissure stapling.

The study will enroll approximately 20 patients at BIDMC, and outcomes will focus on procedure-related complications, physiological measurements (ex., FEV1 by pulmonary function testing) and clinical symptoms (i.e., questionnaires). Patient will be followed for 3-month period, receiving usual standard of care during the 3 months of follow-up. The goal of this protocol is to determine if elimination of significant collateral lung ventilation between lung lobes is possible, and whether such strategy to eliminate collateral lung ventilation between lobes improves outcomes following subsequent EBV placement (i.e. promotes atelectasis of diseased lung segments) in the management of severe COPD/emphysema in appropriate candidates. For subjects in the medical management control group, upon completion of the 3-month F/U period, they will be eligible for EBV if they choose.

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

We plan to approach all EBVs candidates that have < 95% lobar fissure completion. Once the patient agrees to participate and sign the consent, all the screening information collected as part of the standard of care will be extracted retrospectively from the medical records including appointment details, 6MWD, and PFTs results. In addition, during the same visit, health-related quality of life will be measured using the Saint George Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT), and dyspnea will be assessed with the self-reported modified Medical Research Council dyspnea scale (mMRC). After completing these questionnaires and indexes, subjects will be randomized by an opaque envelope technique following a block 2-4 pattern to either Group 1 (Combined robotic or VATS-fissure completion and BLVR with EBVs) or Group 2 (Medical management).

Both surgical stapling for fissure completion and EBVs implantation will be performed during the same procedure and under general anesthesia in the operating room. Depending on the duration of the surgical intervention, the endoscopic valve implantation might be deferred and performed within 48 hours, based on the clinical judgment of the PI, surgeon, and anesthesiologist present during the procedure.

Initial Bronchoscopic Evaluation Initial flexible bronchoscopy will be done by the interventional pulmonologist who will perform the endoscopic valve placement as part of the standard of care. The bronchoscope will be passed via the endotracheal tube and the major airways will be examined. A bronchial wash will be performed with samples sent for culture. If there are unexpected findings, such as a lesion suspicious for carcinoma or secretions suggesting infection, then appropriate clinical samples will be obtained, and the subject will be re-evaluated to determine if they are eligible to undergo the study procedure later. If so, the procedure will be rescheduled. If not, the subject will be withdrawn from the study and will be considered as an "Enrollment Failure" and recorded as such for statistical analysis.

First Chartis Pulmonary System Evaluation of CV Following initial bronchoscopy, evaluation of CV using the Chartis system (Pulmonx Inc., Redwood, CA, USA), will be performed also as part of the standard of care of the patients. If there is no evidence of CV between the target lobe and the adjacent one, the patient will be withdrawn from the study and EBVs will be placed. On the other hand, if the ChartisTM evaluation is positive for CV, the bronchoscope will be withdrawn, and the patient will undergo robotic or VATS completion of the inter-lobar fissure adjacent to the previously selected target lobe.

Robotic or VATS Inter-Lobar Fissure Completion Surgery will be performed with a robotic or VATS approach under inhaled anesthetic agents by an experienced thoracic surgeon from BIDMC. A double-lumen endotracheal tube will be inserted allowing one-lung ventilation and the maximal collapse of the operative lung. The subject will be placed in lateral decubitus with the operative side up. Through small incisions, the surgeon will create a camera port through the intercostal space and then the anterior and posterior inferior ports. Electrocautery will be used for dissection and exposure of the anterior aspect of the hilum. Stapling will then be performed on the incomplete fissure adjacent to the target lobe, using the Endo GIATM (CovidienTM, Mansfield, MA).

An attempt at conversion to a complete fissure will be made, though depending on the anatomy, it may be possible that residual incomplete fissure of up to 5% may be tolerated. Hemostasis will be evaluated. Sterile water will then be used to fill the surgical area, followed by lung inflation and inspection to verify for air leaks at the level of the stapling. If an air leak is detected, suturing, re-stapling, or applying pleural sealants will be used to seal it. If the air leak persists at the site of stapling despite these measures, the subject will still be allowed to proceed to EBVs implantation. Once the fissure is surgically completed, a chest tube will be installed and connected to a digital chest drainage system (ThopazTM Digital Chest Drainage System, Medela Healthcare).

Second Chartis Pulmonary System Evaluation of CV The double-lumen endotracheal tube will be removed, and a single-lumen tube (8.0 to 8.5 mm) inserted. The lung will be completely re-inflated before this evaluation to return them to normal anatomy. Assessment of CV with the ChartisTM system will be performed once again in the same inter-lobar fissure as before following the previously described methods. If the result is negative for CV or there is an improvement in the evaluation, then we will proceed with EBVs implantation.

EBVs Placement Bronchoscopic placement of EBVs will then be performed as part of the standard of care of patients since they meet the previously mentioned inclusion criteria and have no CV, same as patients with an initial negative ChartisTM evaluation. The airway sizing system and a calibrated balloon will be used in the previous re-inflated lung to determine the appropriate Zephyr® valves size to treat the target lobe airways. The treatment algorithm is complete occlusion of one lobe by using valves to occlude all segments of the lobe. Either upper or lower lobes may be targeted for treatment. The lobe will have been selected by the CT core laboratory based on imaging with computed tomography. However, the PI can choose the alternate eligible lobe if the airway in the primary eligible lobe is overly challenging for valve implantation, such as difficulty associated with the underlying airway anatomy.

A valve may be removed and replaced with a different size valve during the procedure and a valve may also be removed and replaced to improve the location. However, a valve may not be repositioned during the procedure. It is intended that the investigator occlude all segments of the target lobe by placing valves into segmental or sub-segmental airways. There is anatomic variability in the number and size of segments in a lobe, so this protocol does not have a limit on the number of valves to be used. Subjects who do not have any endobronchial valves placed at the end of the bronchoscopy procedure will be withdrawn.

Follow-up Period After BLVR with EBVs, patients will be placed on a standardized follow-up protocol used for individuals that underwent BLVR. All procedures and appointments following EBV placement will be considered standard of care. Data from follow-up appointments at 14 days and 3 months will be collected from the medical records retrospectively including appointment details, complications, CT-scan results, 6MWD, and PFTs results. TLVR will be assessed at 3 months using the CT scans performed on patients as part of their standard of care. The only procedures that will be considered research after the initial surgical intervention would be the measurement of health-related quality of life with the SGRQ and CAT, and dyspnea assessment with the self-reported mMRC at every follow-up appointment.

Crossover Group After the patient allocated to the medical management, the arm is followed for 3 months, they will be offered the robotic or VATS fissure completion procedure. It will be completely up to the candidates to undergo the intervention. If they decide that they want to proceed with surgery, the previously described methods will be used including the same surgical technique, same postoperative management, and same follow-up timelines and datapoints.

研究の種類

介入

入学 (推定)

20

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • Beth Israel Deaconess Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

40年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age 40 to 75 years.
  • Stable with less than 10mg prednisone (or equivalent) daily.
  • Nonsmoking for 4 months prior to screening and willing to not smoke during the study duration.
  • Completed a supervised pulmonary rehabilitation program less than equal to 12 months prior to the baseline exam or is regularly performing maintenance respiratory rehabilitation if initial supervised therapy occurred greater than 12 months prior.
  • Current pneumococcus vaccination.
  • Current influenza vaccination.
  • Willing and able to complete protocol required study follow-up assessments and procedures.

Exclusion Criteria:

  • > 95% fissure completion on high-resolution chest CT-scan (HRCT) or StratX evaluation with a Chartis evaluation negative for collateral ventilation.
  • Clinically significant (greater than 4 tablespoons per day) mucus production.
  • Myocardial infarction within 6 months of screening.
  • Uncontrolled congestive heart failure.
  • Three or more pneumonia episodes in last year.
  • Three or more COPD exacerbation episodes in the last year.
  • Prior lung transplant, LVRS, bullectomy, or lobectomy.
  • Clinically significant bronchiectasis.
  • Unable to safely discontinue anticoagulants or platelet activity inhibitors for 7 days.
  • Uncontrolled pulmonary hypertension (systolic pulmonary arterial pressure >45mmHg) or evidence or history of CorPulmonale as determined by a recent echocardiogram (completed within the last 3 months prior to screening visit).
  • Left ventricular ejection fraction (LVEF) less than 40% as determined by a recent echocardiogram (completed within the last 3 months prior to screening visit).
  • Resting bradycardia (<50 beats/min), frequent multifocal PVCs, complex ventricular arrhythmia, sustained SVT.
  • Post-bronchodilator FEV1 less than 15% or greater than 45% of the predicted value at screening.
  • TLC less than 100% predicted (determined by body plethysmography at screening).
  • RV less than 150% predicted in patients with heterogeneous emphysema or less than 200% predicted in patients with homogeneous emphysema (determined by body plethysmography at screening).
  • DLCO less than 20% of the predicted value at screening.
  • Post-rehabilitation 6-minute walk distance less than 100 meters or greater than 450 meters at screening.
  • PaCO2 greater than 50mmHg on room air at screening.
  • PaO2 less than 45mmHg on room air at screening

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
介入なし:Medical management group

COPD patients with severe emphysema and incomplete lobar fissures will be placed on maximal medical therapy for 3 months. At the end of this 3 month period, patients will fill in an additional set of quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. New pulmonary function testing will be performed and crossover to the intervention group will be offered.

実験的:Intervention group

COPD patients with severe emphysema and incomplete lobar fissures will undergo video-assisted thoracic surgery fissure completion and valves placement. After a 3 month follow-up period, patients will fill additional quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. Pulmonary function testing and a high-resolution CT scan will be performed at the end of the 3-month postoperative follow-up.

The lobar fissure adjacent to the target lobe will be completed using a surgical stapler through robotic or video-assisted thoracic surgery.

Endobronchial valves will be placed in the target lobe after the fissure completion.

実験的:Crossover group

Subjects allocated to the medical management group will be offered to crossover after the 3 months follow-up period. The same procedure as in the intervention group will be performed. Follow-up after surgery will be the same as in the intervention group.

The lobar fissure adjacent to the target lobe will be completed using a surgical stapler through robotic or video-assisted thoracic surgery.

Endobronchial valves will be placed in the target lobe after the fissure completion.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Prove that inter-lobar fissures can be completed to at least 95% via robotic thoracic surgery or VATS in severe emphysema patients
時間枠:2 years

We will determine that we met this feasibility objective if the target inter-lobar fissure can be completed in at least 90% of the patients undergoing surgery.

2 years
Prove that patients consented for the procedure will ultimately undergo the intervention
時間枠:2 years

We will determine that the study is feasible if at least 90% of consented patients in the intervention arm undergo the procedure.

2 years
Incidence of severe adverse events
時間枠:Through study completion, an average of 2 years

We will actively monitor and record the severe adverse events that require any kind of additional intervention (medical or surgical) during and after the combined procedure. In case the treating physicians consider that the complications seen in patients outweigh the benefits obtained, the surgical technique will be revised and possible changes will be discussed.

Through study completion, an average of 2 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Percentage of patients to achieve target lung volume reduction
時間枠:2 years

Describe the percentage of patients that achieve target lung volume reduction of at least 350mL at three months after the combined procedure.

2 years
Percentage of patients with quality of life improvement
時間枠:2 years

Describe the changes in quality of life based on three subjective questionnaires that will be given to patients at baseline and three months after any intervention.

2 years
Percentage of patients with significant changes in pulmonary function testing
時間枠:2 years

Describe the changes in PFTs after the intervention.

2 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年8月1日

一次修了 (推定)

2026年12月31日

研究の完了 (推定)

2027年1月1日

試験登録日

最初に提出

2021年3月9日

QC基準を満たした最初の提出物

2021年3月12日

最初の投稿 (実際)

2021年3月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2021P000049

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。